课题基金 / 基金详情

MICROINVASIVE TREATMENT OF SLEEP APNEA WITH THE LINGUAFLEX TISSUE RETRACTOR II

MICROINVASIVE TREATMENT OF SLEEP APNEA WITH THE LINGUAFLEX TISSUE RETRACTOR II
使用 LINGUAFLEX 组织牵开器 II 微创治疗睡眠呼吸暂停
批准号:
7928533
负责人:
IRA SANDERS
金额:
$19.74万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-06-01 至 2012-05-31

项目摘要

项目成果

IRA SANDERS的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):该提案要求为第二代新型微创睡眠呼吸暂停设备--LanguaFlex组织牵引器(LTR-II)的开发和概念验证测试提供资金。阻塞性睡眠呼吸暂停(OSA)是一种发病率和死亡率较高的常见病。据估计,多达20%的美国人口受到影响,而大多数患者仍未得到诊断。一项名为LanguaFlex舌头拉伸器(LTR-I)的新技术已经开发出来,最近在临床前和临床试验中进行了测试。人体试验证明了第一代设备的安全性,该疗法在大约三分之二的受试者中有效地减少了呼吸道阻塞。第一代LTR通过注射针头插入舌根中线,工作原理是防止睡眠期间舌根向后塌陷。它是为治疗更严重的阻塞性睡眠呼吸暂停综合征而设计的。正在开发ltr-II来治疗轻到中度的疾病。它缩回上呼吸道的所有三个区域,它们的塌陷直接导致阻塞性睡眠呼吸暂停综合征的气道阻塞,即舌根、软腭部和咽侧壁。初步工作表明,这种带有第二代装置的横向方法具有很好的前景。这项研究将在动物模型中提供LTR-II的安全性和有效性的概念证明。此外,将在人体身体模型中研究LTR-II和上呼吸道的组织相互作用和张力特性,以表征设备的特性,以实现最佳功能。这两个模型都成功地应用于LTR-I的研制。与第一代设备相比,侧向技术还具有侵入性更小、痛苦更小、患者更舒适的优势,同时更容易操作。第一阶段临床试验的SBIR建议计划在这些研究完成时提交。如果成功,这些设备将为CPAP提供一种可接受的替代方案,并在所有疾病严重程度的OSA治疗方面取得重大进展。 与公共健康相关:睡眠呼吸暂停是一种影响数百万美国人的疾病,患者在睡眠中停止呼吸10秒或更长时间。这些症状被称为呼吸暂停。患有严重睡眠呼吸暂停症的人在夜间每小时可能会有数百次这样的发作。未经治疗的睡眠呼吸暂停会增加高血压、中风、糖尿病甚至死亡的风险。目前治疗睡眠呼吸暂停的方法包括大手术或终生使用夜间呼吸器。该项目允许开发一种新的治疗方法,旨在以舒适和可接受的方式治疗睡眠呼吸暂停。这种疗法包括在局部麻醉下将一个薄的、有弹性的植入物插入舌侧。该装置将在动物和人类身体标本上进行测试。这些研究将导致该设备的进一步开发用于临床试验。该项目的具体目标是开发和测试这种预防睡眠呼吸暂停的新医疗设备,并在随后的后续研究中进行一项小型安全临床试验。
英文摘要
DESCRIPTION (provided by applicant): The proposal requests funding for the development and proof-of-concept testing of the second generation of a novel, minimally invasive sleep apnea device, the LinguaFlex Tissue Retractor (LTR-II). Obstructive sleep apnea (OSA) is a common disorder with high morbidity and mortality. It is estimated that up to 20% of the United States population is affected while most patients remain undiagnosed. A new technology, the LinguaFlex Tongue Retractor (LTR-I), was developed and recently tested in pre-clinical and clinical trial. The human trial proved safety of the first-generation device and the therapy was effective in reducing airway obstructions in approximately two-thirds of the subjects tested. The first-generation LTR is inserted in the tongue midline by a needle injection and works by preventing backward collapse of the tongue base during sleep. It was designed to treat the more severe cases of OSA. LTR-II is being developed to treat mild to moderate form of the disease. It retracts all three areas of the upper airway whose collapse directly contributes to airway obstructions in OSA, namely the tongue base, the soft palate and the lateral pharyngeal walls. Preliminary work shows that this lateral approach with the second-generation device is highly promising. This study will provide proof-of-concept of the safety and efficacy of LTR-II in an animal model. Moreover, tissue interaction and tension characteristics of LTR-II and the upper airway will be studied in the human cadaver model to characterize the device specifics for optimum function. Both models were successfully used in the development of LTR-I. The lateral technique also offers the advantage in being less invasive and painful and more comfortable for the patients while being easier to perform compared to the first-generation device. An SBIR proposal for Phase I clinical trial is planned for submission at the completion of these studies. If successful, the devices will provide an acceptable alternative to CPAP and a significant advance in OSA treatment across all severity range of the disease. PUBLIC HEALTH RELEVANCE: Sleep apnea is a disorder that affects millions of Americans in which a person stops breathing during sleep for 10 seconds or longer. These episodes are known as apneas. People who have a severe form of sleep apnea can have hundreds of such episodes per hour during the night. Untreated sleep apnea results in increased risks for high blood pressure, stroke, diabetes, and even death. Current therapies for sleep apnea include major surgery or lifelong use of a nightly respirator. This project allows for the development of a new therapy intended to treat sleep apnea in a comfortable and acceptable manner. The therapy involves the insertion of a thin, elastic implant into the side of the tongue, under local anesthesia. The device will be tested in animals and human cadaver specimen. These studies will lead to further development of the device for clinical trial. The specific goals of this project are to develop and test this new medical device to prevent sleep apnea and later perform a small safety clinical trial in a follow up study.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Anatomical Basis of Human Tongue Biomechanics
THE ANATOMICAL BASIS OF HUMAN TONGUE BIOMECHANICS
The Anatomical Basis of Human Tongue Biomechanics
The Anatomical Basis of Human Tongue Biomechanics
海外基金